The IRGQ Knockout KYSE-150 Polyclonal Cells product is a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt the IRGQ gene in the human KYSE-150 esophageal squamous cell carcinoma line. This heterogeneous pool of gene-edited cells is generated through CRISPR/Cas9-mediated gene disruption, offering a loss-of-function model that maintains the natural variation of a polyclonal population while avoiding clonal selection artifacts.
The host KYSE-150 cell line is a well-differentiated human esophageal squamous cell carcinoma model derived from a male patient. It is frequently employed in cancer research due to its robust growth characteristics, invasive potential, and representation of relevant oncogenic pathways. This background provides a valuable system for exploring how IRGQ influences tumor cell biology, including autophagy and metabolic regulation.
IRGQ encodes a mitochondrial outer membrane protein that serves as a receptor for the kinase TBK1, playing a pivotal role in mitophagy and innate immune responses. Upon mTORC1 inhibition, nutrient deprivation, or mitochondrial stress, IRGQ recruits TBK1 to mitochondria, where TBK1 phosphorylates optineurin and p62/SQSTM1. This phosphorylation promotes LC3 lipidation and the engulfment of damaged mitochondria by autophagosomes. IRGQ interacts with TBK1 and the translocase TOM70, and its activity is modulated by mTORC1, integrating nutrient-sensing pathways with mitochondrial quality control and immune signaling.
In esophageal squamous cell carcinoma, IRGQ-regulated mitophagy and innate immunity may critically impact tumor progression, metabolic reprogramming, and drug sensitivity. Disruption of IRGQ in KYSE-150 cells enables detailed analysis of how defective mitochondrial clearance affects cancer cell proliferation, apoptosis, and response to chemotherapy. This model also permits exploration of the interplay between autophagy and tumor microenvironment interactions, including immune evasion mechanisms.
This polyclonal knockout population is compatible with a range of advanced techniques. Mitophagy flux can be assessed using the mt-Keima assay, immunofluorescence imaging of LC3 puncta, or Western blotting for p62 degradation and LC3 lipidation. Co-immunoprecipitation assays allow probing of IRGQ-TBK1-TOM70 interactions, while Seahorse analysis measures mitochondrial respiration and glycolysis. Applications include studying mTORC1-driven signaling, innate immune pathways in cancer, and mechanisms of drug resistance. For further technical information, please contact Ascent Research.
